Diagnostic, Prognostic, and Therapeutic Value of Circulating miRNAs in Heart Failure Patients Associated with Oxidative Stress

Abstract EN

Heart failure is a major public health problem especially in the aging population (≥65 years old), affecting nearly 5 million Americans and 15 million European people.

Effective management of heart failure (HF) depends on a correct and rapid diagnosis.

Presently, BNP (brain natriuretic peptide) or N-terminal pro-brain natriuretic peptide (NT-proBNP) assay is generally accepted by the international community for diagnostic evaluation and risk stratification of patients with HF.

However, regardless of its widespread clinical use, BNP is still encumbered by reduced specificity.

As a result, diagnosis of heart failure remains challenging.

Although significant improvement happened in the clinical management of HF over the last 2 decades, traditional treatments are ultimately ineffective in many patients who progress to advanced HF.

Therefore, a novel diagnostic, prognostic biomarker and new therapeutic approach are required for clinical management of HF patients.

Circulating miRNAs seem to be the right choice for novel noninvasive biomarkers as well as new treatment strategies for HF.

In this review, we briefly discuss the diagnostic, prognostic, and therapeutic role of circulating miRNAs in heart failure patients.

We also mentioned our own technique of extraction of RNA and detection of circulating miRNAs from human plasma and oxidative stress associated miRNAs with HF.